WILMINGTON, DE — AstraZeneca has announced it is voluntarily recalling a single lot (#JB5047) of physician-sample bottles of its antiplatelet agent ticagrelor (Brilinta/Brilique) after a report that one such bottle contained pills of another drug.
Ticagrelor is widely used for secondary prevention in patients with acute coronary syndromes (ACS) and to reduce the risk of stent thrombosis after coronary intervention for ACS.
The recalled bottles are marked to contain eight tablets of ticagrelor 90 mg, which are round and yellow. The tainted bottle reportedly also contained tablets of lesinurad (Zurampic) 200 mg, which are oval-shaped and blue, also from AstraZeneca, and indicated as add-on therapy for patients with gout already on xanthine oxidase inhibitors, according to the company.
"AstraZeneca is notifying physicians by recall letter and is arranging for return of all recalled products," it said.
Heartwire from Medscape © 2017 Medscape, LLC
Cite this: Ticagrelor (Brilinta) Professional Samples Recalled, 1 Lot - Medscape - May 26, 2017.